ABSTRACT
INTRODUCTION
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder affecting both children and adults, characterised by a platelet diagnosed' (from diagnosis until 3 months), 'persistent ITP' (3-12 months) and 'chronic ITP' (ITP lasting for more than 12 months) [2] . Chronic primary ITP in adults is slightly more common in women of childbearing age but the sex incidence is similar in patients over 60 [2, 3] .
The incidence of ITP in adults is around 4 per 100,000 people per year, with a UK prevalence of up to 24 per 100,000 people [4] [5] [6] .
Bleeding is highly variable and there is great heterogeneity in primary ITP. Bleeding is most commonly mucocutaneous, involving gum bleeding, blood blisters in the mouth and menorrhagia. Major bleeding is not common if the platelet count is above 30 9 10 9 /l. The most serious form of bleeding, intracranial haemorrhage, is rare and is most often seen in older patients who have additional comorbidities and in patients who fail to respond to therapy [7] . The yearly risk of fatal haemorrhage is around 1.6-3.9% [8] . This risk varies with age, at 0.4% per annum in those below the age of 40 years to 13% per annum over patients over 60 years of age.
The aims of this review are to provide a brief overview of ITP and its current management.
The main emphasis of the review is on the recently introduced TPO receptor agonists focussing on published trial data. Both romiplostim and eltrombopag are discussed in detail, including recently published studies that show the unexpectedly high rate of sustained responses to these agents following their discontinuation.
CLINICAL FEATURES
Paediatric and adult ITPs are quite different in terms of their underlying pathophysiology and clinical outcomes. In children, ITP may follow a viral infection or immunisation. In most children the disease remits spontaneously by 6 months with little need for medical treatment. Around 15% of children will go on to develop chronic ITP.
In the adult form of the disease there is usually no prodrome. Instead, the patient may notice an increase in bruising, or petechiae. In many cases ITP in adults is picked up by chance when the patient has a full blood count for other reasons, for example, preoperatively. This is seen particularly in the elderly when nearly a third will be diagnosed by chance.
ITP in adults is extremely heterogeneous. Many patients have no clinical problems related to their thrombocytopenia even at very low platelet counts, while other patients may have bleeding from the outset and a study of practice in Europe over 1 year showed that 40% of patients had no bleeding at all despite low platelet counts and required no treatment [9] . The platelet count by itself is an unreliable predictor of clinical outcome. Many factors contribute towards the bleeding risk including age, comorbidities, medication, prior bleeding history and other factors not yet identified. In some patients an autoantibody may bind to a critical epitope on the platelet glycoprotein and interfere with platelet function. Autoantibodies reacting with glycoprotein (GP)IIb/IIIa may affect platelet aggregation; these are the most common autoantibodies seen in primary ITP [10] . Antibodies against GPIb/IX may impair platelet adhesion to the subendothelial matrix, thereby causing severe bleeding for the level of platelet count. Other autoantibodies including antiphospholipid antibodies are detected in up to 30% of patients with ITP. These may affect platelet and vascular function. Overall, however, despite the severity of the thrombocytopenia, severe bleeding is not common in ITP, in contrast with thrombocytopenia following chemotherapy or bone marrow failure [11] .
MANAGEMENT OF ADULT ITP
ITP in adults is a disease with low morbidity and mortality. Most patients with ITP have few problems related to the thrombocytopenia but a minority may be resistant to treatment and have a platelet count that is chronically low.
After the publication of the original American Society of Hematology guideline in 1996 [12] there was a tendency to treat most patients whose platelet count was \30 showed that the treatments used contributed significantly to an increase in morbidity and mortality in their cohort [13] . Contrary to what might be expected, half of the deaths observed in the study were attributable to the treatment used rather than haemorrhage. MacMillan showed this to be a particular problem in patients who had failed splenectomy and required continuing immune suppressive therapy [7] .
Patients with ITP who have low platelet counts bleed less than patients with aplastic anaemia or chemotherapy-induced thrombocytopenia at equivalent platelet The main aim of treatment is to achieve a safe platelet count for each patient on a case-by-case basis [14] . The intention is not to normalise the platelet count. In general, treatment is seldom required when platelets are greater than 20 [20] and may also reduce the need for splenectomy [21] .
SECOND-LINE THERAPY
If a patient fails to respond to first-line treatment or relapses following a response there may be a need to introduce a second-line treatment. These treatments include medical therapies and splenectomy.
The medical treatments used as second-line therapy have undergone few randomised controlled trials and a systematic review covering nearly 700 patients showed that complete remission rates rarely exceed 15% and few of the individual studies have sufficiently large numbers of truly refractory patients to make a definitive recommendation [22] . Response to rituximab is generally seen after 1-2 weeks but in some patients a response may be seen up to 2 months after the last infusion The 12-week study of romiplostim versus placebo was carried out in splenectomised and non-splenectomised Japanese patients with chronic severe ITP [62] . The mean increase in platelet count from baseline was 110 9 10 9 /l in those receiving romiplostim compared with 2 9 10 9 /l in the placebo arm.
THROMBOPOIETIN RECEPTOR AGONISTS
Results are available for up to 5 years continuous dosing involving 292 adults. Platelet counts of greater than 50 9 10 9 /l were recorded at least once by more than 95% of subjects in the study [63] . 
TRAs MAY INDUCE SUSTAINED REMISSIONS
Romiplostim and eltrombopag are licensed for use in adults with chronic ITP. The drugs stimulate megakaryocyte proliferation and platelet production. The expectation when using these agents is that the platelet count will rise when taking the TRA but will drop to baseline levels when the drug is stopped. These drugs were not licensed with any curative intent. However, published reports show that a proportion of patients may achieve a sustained response to the TRAs even after the drugs have been stopped.
One study of 54 adults treated with at least one TRA over a 5-year period found that 20 of 28 patients (28.5%) who achieved a complete response had a sustained response after stopping the TRA. The median follow-up was no predictive factors were identified [71] . A more recent phase 2, single-arm study looked at 75 patients less than 6 months from presentation who had failed first-line treatment and had a continuing platelet count of less than 30 treated with romiplostim [72] . Responses occurred rapidly in more than 90% and long-term remission occurred in 32%, which were sustained for more than 6 months off all treatment. Again no predictive clinical features could be identified but the studies confirm that a significant proportion of patients can safely stop treatment.
A large series of patients (260) treated with eltrombopag was evaluated by Gonzalez-Lopez and colleagues [73] . Out of 49 evaluable patients, 26 (53%) had a sustained response after stopping eltrombopag with a median follow-up of 9 months.
From the published data, therefore, it would appear that 25-30% of patients receiving a TRA may expect a sustained response on stopping the drug. The mechanism for these sustained responses is not clear. Some of these patients may have had a spontaneous remission but the patients in all reported studies had received several prior treatments and had severe thrombocytopenia for some considerable time.
Spontaneous remission is therefore unlikely.
The TRAs may have an effect on regulatory T cells (Tregs). These cells naturally suppress autoimmune disease [74] . From studies of rituximab used for the treatment of ITP it would appear that those patients who respond to rituximab normalise their Tregs; those that fail to respond to rituximab do not [75] . 
